Explore more publications!

Health Insider Virgin Islands: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Insider Virgin Islands.

Press releases published on November 6, 2025

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update 
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
Teknova Reports Third Quarter 2025 Financial Results
Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
Progyny, Inc. Announces Third Quarter 2025 Results
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Statement of total voting rights and shares forming the company’s share capital as October 20, 2025
  Information relative au nombre total de droits de vote et d’actions composant le capital social  au 20 octobre 2025
Combined General Meeting of November 27, 2025 - Availability of the preparatory documents
Assemblée Générale Mixte du 27 novembre 2025 - Modalités de mise à disposition des documents préparatoires
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions